NCT00626704View on ClinicalTrials.gov

Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

August 31, 2009

Study Completion Date

March 31, 2011

Conditions
Locally Advanced or Metastatic, Unresectable Soft Tissue SarcomaSarcomaSoft Tissue Sarcoma
Interventions
DRUG

AMG 655

AMG 655 is an investigational, fully human monoclonal agonist antibody that selectively binds to Death Receptor-5 (DR5).

OTHER

Placebo

Inactive dummy AMG 655 (to maintain blind)

DRUG

Doxorubicin

Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of Daunorubicin.

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY